Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients WithRASWild-Type Advanced Colorectal Cancer-Reference-Cited by-同舟云学术

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients WithRASWild-Type Advanced Colorectal Cancer

Published:2016-05-01 Issue:5 Volume:2 Page:633
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Seligmann Jenny F.¹,Elliott Faye¹,Richman Susan D.¹,Jacobs Bart²,Hemmings Gemma¹,Brown Sarah³,Barrett Jennifer H.¹,Tejpar Sabine²,Quirke Philip¹,Seymour Matthew T.¹

Affiliation:

1. Leeds Institute of Cancer and Pathology, University of Leeds, St James’s University Hospital, Leeds, United Kingdom

2. Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium

3. Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EREG silencing inhibits tumorigenesis via inactivating ERK/p38 MAPK pathway in pancreatic ductal adenocarcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression;npj Precision Oncology;2024-09-06

3. Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer;Frontiers in Oncology;2024-05-28

4. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road;Frontiers in Pharmacology;2024-04-22

5. Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7;Proceedings of the National Academy of Sciences;2024-03-14